Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT06969807

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06969807
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06969807. Allocation not applicable; no masking; primary purpose treatment. Start 2025-06-09 (actual); primary completion 2026-08-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease
Acronym
MSC-DKD-001
Condition
Diabetic Kidney Disease (DKD)
Intervention (Drug)
Amimestrocel
Lead sponsor
Chinese PLA General Hospital (class: other)

Record details

Record id
cardio:ct-nct06969807
Content hash
2196f104603764f7cdd13cbf4c5ee8dffc23a27e0d30cc1c13a5d211795720d4